Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
Crossref DOI link: https://doi.org/10.1136/bmjopen-2016-011714
Published Online: 2016-06-30
Published Print: 2016-06
Update policy: https://doi.org/10.1136/crossmarkpolicy
Zhang, Shu
Mao, Xiao-dong
Wang, Hai-tao
Cai, Feng
Xu, Jing
